Sandoz Group AGSDZXF 17 5-Year Yield-on-Cost % is 1.14 as of Jul. 09, 2026, which is 21% above its 10-year median of 0.94. GuruFocus rates SDZXF with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 516 Drug Manufacturers companies, Sandoz Group AG ranks worse than 68.99% on this metric.
Sandoz Group AG's yield on cost for the quarter that ended in Dec. 2025 was 1.14.
The historical rank and industry rank for Sandoz Group AG's 5-Year Yield-on-Cost % or its related term are showing as below:
SDZXF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.75 Med: 0.94 Max: 1.39
Current: 1.14
During the past 4 years, Sandoz Group AG's highest Yield on Cost was 1.39. The lowest was 0.75. And the median was 0.94.
SDZXF's 5-Year Yield-on-Cost % is ranked worse than 68.99% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.255
vs SDZXF: 1.14
Sandoz Group AG (OTCPK:SDZXF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sandoz Group AG 5-Year Yield-on-Cost % Related Terms
SDZXF vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's 5-Year Yield-on-Cost % falls into.
Sandoz Group AG 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Sandoz Group AG is calculated as
Sandoz Group AG (SDZXF) has a 5-Year Yield-on-Cost % of 1.14 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sandoz Group AG and its competitors. This is 21% above median its historical median of 0.94. Over the past decade, Sandoz Group AG's 5-Year Yield-on-Cost % has ranged from 0.75 to 1.39. According to the industry distribution chart, Sandoz Group AG ranks #356 out of 516 companies in the Drug Manufacturers industry, placing it in the top 69%.
Is Sandoz Group AG's 5-Year Yield-on-Cost % too high?
Sandoz Group AG's current 5-Year Yield-on-Cost % of 1.14 is 21% above median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 1.39. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.26. Sandoz Group AG's value of 1.14 is 49.4% below this industry median. Based on the distribution chart, Sandoz Group AG ranks #356 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #356 out of 516 companies for 5-Year Yield-on-Cost %. This places Sandoz Group AG in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.26. Sandoz Group AG's value of 1.14 is 49.4% below this benchmark. Historically, Sandoz Group AG's own 5-Year Yield-on-Cost % has ranged from 0.75 to 1.39 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 2.26, Sandoz Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.26, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current 5-Year Yield-on-Cost % of 1.14 is 49.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current 5-Year Yield-on-Cost % is 1.14, which is 21% above median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current 5-Year Yield-on-Cost % of 1.14. The current 5-Year Yield-on-Cost % is 1.14, which is 21% above median its 10-year median of 0.94 and 49.4% below the Drug Manufacturers industry median of 2.26. Sandoz Group AG's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current 5-Year Yield-on-Cost % is 1.14 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
17GF Score
Get the complete analysis for SDZXF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDZXF has been successfully added to your 